Erythropoietin (epo) Or Derivative Patents (Class 514/7.7)
  • Patent number: 10604779
    Abstract: Disclosed is a highly efficient method for production of highly pure mutant-type human erythropoietin. The method is for production of mutant-type human erythropoietin, in which a transformed mammalian cell is allowed to produce the mutant-type human erythropoietin, and the supernatant of the culture is subjected to hydrophobic column chromatography, multimodal anion exchange column chromatography, anion exchange column chromatography, phosphate group affinity column chromatography, and gel filtration column chromatography, in this order.
    Type: Grant
    Filed: March 7, 2017
    Date of Patent: March 31, 2020
    Assignee: JCR PHARMACEUTICALS CO., LTD.
    Inventors: Shinji Kakimoto, Miroslav Matev, Tsuyoshi Fukui, Yukichi Hatano, Junya Tani, Kazutoshi Mihara, Kenichi Takahashi, Atsushi Sugimura
  • Patent number: 10456346
    Abstract: The invention relates to cosmetic formulations and new peptide related entities designed for the cosmetic treatment of the human skin. In more detail, the invention is related to peptides that target CD90 positive tissue cells and correspond to or derive from the partial sequence of erythropoietin (EPO) but do not substantially elicit a hematopoietic but a tissue regenerative and protective effect. In particular, the invention discloses EPO-derived tissue-protective peptides in functional relation to lipid structures and agents that trigger vasculature relaxation and promote transdermal transport of the polypeptide entities to the targeted skin cells.
    Type: Grant
    Filed: November 7, 2017
    Date of Patent: October 29, 2019
    Assignee: ASC REGENITY LTD.
    Inventor: Augustinus Bader
  • Patent number: 9920098
    Abstract: An object of the present invention is to develop techniques to create novel engineered protein ligands that maximize the binding capacity and binding efficiency to a target molecule of affinity separation matrices on which the protein ligands are immobilized. The present invention provides protein ligands (variants) that can be immobilized on carriers in a manner shown in schematic FIG. 1(4)-(15), as well as antibody affinity separation matrices obtained by immobilizing such a protein ligand on a water-insoluble carrier. The affinity separation matrices are characterized by their excellent binding capacity and binding efficiency to a target molecule.
    Type: Grant
    Filed: September 24, 2013
    Date of Patent: March 20, 2018
    Assignee: KANEKA CORPORATION
    Inventors: Shinichi Yoshida, Dai Murata, Fuminori Konoike, Keita Iguchi, Tomoyuki Nakaishi, Masahiro Hayashi
  • Patent number: 9827294
    Abstract: Embodiments are directed to compositions and methods of treating migraine and related neurological disorders. In certain aspects, methods and compositions are for reducing cortical spreading depression and/or suppressing the neurochemical basis for chronic and acute migraine events, and provide methods and pharmaceutical compositions related to both acute and preventive therapies for migraine events and related headaches.
    Type: Grant
    Filed: June 2, 2016
    Date of Patent: November 28, 2017
    Assignee: The University of Chicago
    Inventors: Richard Kraig, Aya Pusic, Heidi Mitchell, Yelena Grinberg, Marcia Kraig
  • Patent number: 9657098
    Abstract: The present application relates to antibodies that specifically bind to hepcidin and methods of using the antibodies. Another aspect relates to antibodies which bind hepcidin and regulate iron homeostasis. Another aspect relates to the use of humanized antibodies which bind hepcidin for the treatment of a disease or condition associated with hepcidin.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: May 23, 2017
    Assignee: INTRINSIC LIFESCIENCES, LLC
    Inventors: Mark Westerman, Vaughn Ostland, Huiling Han, Patrick Gutschow, Keith Westerman, Gordana Olbina
  • Patent number: 9399053
    Abstract: Embodiments are directed to compositions and methods of treating migraine and related neurological disorders. In certain aspects, methods and compositions are for reducing cortical spreading depression and/or suppressing the neurochemical basis for chronic and acute migraine events, and provide methods and pharmaceutical compositions related to both acute and preventive therapies for migraine events and related headaches. In particular embodiments, treatment involves IL-11, interferon-gamma, or an IGF inducer such as IGF-1 or insulin.
    Type: Grant
    Filed: July 20, 2012
    Date of Patent: July 26, 2016
    Assignee: The University of Chicago
    Inventors: Richard Kraig, Aya Pusic, Heidi Mitchell, Yelena Grinberg, Marcia Kraig
  • Patent number: 9314504
    Abstract: The invention relates to a novel use of the members of the IL-10 cytokine family in wound healing. Particularly, the invention relates to the use of the member of the IL-10 cytokine family in the promotion of the proliferation and the migration of keratinocyte cells in wound healing.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: April 19, 2016
    Assignees: TAIPEI MEDICAL UNIVERSITY, CHI MEI MEDICAL CENTER
    Inventors: Ching-Hsi Hsing, Ching Hua Yeh, Li-Yun Wang, Ding Ping Sun
  • Patent number: 9206168
    Abstract: The present invention provides a compound which enhances the production of erythropoietin. The present invention provides a compound represented by the formula (1) wherein R1: an aromatic hydrocarbon ring group or an aromatic heterocyclic group; R2: a hydrogen atom, an alkyl group, or a heterocycloalkyl group; R3: a hydrogen atom or an alkyl group; A: a hydrogen atom or a hydroxy group; L: —NHCO— or —OCH2—; and X: a nitrogen atom or ?CH—.
    Type: Grant
    Filed: September 24, 2014
    Date of Patent: December 8, 2015
    Assignee: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Tatsuya Nishi, Naoki Tanaka, Ryoko Kitazawa, Riki Goto, Takashi Ishiyama
  • Publication number: 20150147345
    Abstract: This document relates to conjugates of a biologically active molecule or a derivative thereof and functionalized (e.g., mono- or bi-functional) polymers (e.g., polyethylene glycol and related polymers) as well as methods and materials for making and using such conjugates.
    Type: Application
    Filed: June 12, 2013
    Publication date: May 28, 2015
    Inventor: Marek Kwiatkowski
  • Publication number: 20150148291
    Abstract: A polypeptide and polynucleotides comprising at least two carboxy-terminal peptides (CTP) of chorionic gonadotrophin attached to a non-human peptide-of-interest are disclosed. Pharmaceutical compositions comprising the non-human polypeptides and polynucleotides of the invention and methods of using both human and non-human polypeptides and polynucleotides are also disclosed.
    Type: Application
    Filed: November 26, 2014
    Publication date: May 28, 2015
    Inventors: UDI EYAL FIMA, GILI HART
  • Publication number: 20150147399
    Abstract: The present invention provides a pharmaceutical composition formulated for oral delivery, comprising a particulate non-covalently associated mixture of pharmacologically inert silica nanoparticles having a hydrophobic surface, a polysaccharide, and a biologically active protein or peptide suspended in an oil. The present invention further provides methods of manufacturing same and therapeutic methods utilizing same for oral delivery of a therapeutic protein or peptide.
    Type: Application
    Filed: December 9, 2014
    Publication date: May 28, 2015
    Inventors: Alexander Vol, Orna Gribova
  • Publication number: 20150141331
    Abstract: A polypeptide and polynucleotides comprising at least two carboxy-terminal peptides (CTP) of chorionic gonadotrophin attached to a non-human peptide-of-interest are disclosed. Pharmaceutical compositions comprising the non-human polypeptides and polynucleotides of the invention and methods of using both human and non-human polypeptides and polynucleotides are also disclosed.
    Type: Application
    Filed: November 26, 2014
    Publication date: May 21, 2015
    Applicant: OPKO Biologics Ltd.
    Inventors: Fuad FARES, Udi Eyal Fima
  • Publication number: 20150140127
    Abstract: Provided is a method for detecting injury to the brain comprising: a) determining the level of a tight junction (TJ) protein in exosomes isolated from a test sample from a subject, wherein the TJ protein is occludin, claudin-3, claudin-5, claudin-12, ZO-1, ZO-2, ZO-3, JAM-A, JAM-B or JAM-C, or any combination thereof; b) comparing the level of the TJ protein in the test sample to the level of the TJ protein in a control sample, wherein an elevated level of the TJ protein in the test sample relative to the level of the TJ protein in the control sample indicates that the subject has an injury to the brain.
    Type: Application
    Filed: June 25, 2013
    Publication date: May 21, 2015
    Applicant: TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventors: Servio H. Ramirez, Slava Rom, Yuri Persidsky
  • Patent number: 9034820
    Abstract: The invention generally relates to compositions and methods of their use. More specifically, the invention relates to the use of a compound in modulating erythropoiesis in a subject by mediating the activity and/or quantity of a member present in the LPA3-mediated signaling pathway, such as lysophosphatidic acid receptor subtype 3 (LPA3).
    Type: Grant
    Filed: March 13, 2012
    Date of Patent: May 19, 2015
    Inventor: Hsinyu Lee
  • Publication number: 20150133378
    Abstract: A method for identifying a kidney transplant recipient at an increased risk of developing interstitial fibrosis or tubular atrophy which comprises obtaining a post-transplant urine sample from the kidney transplant recipient; measuring the level of clusterin in the urine sample; comparing the level of clusterin in the patient sample to the level of clusterin in a control sample from the urine of a non-fibrotic kidney transplant recipient; diagnosing a kidney transplant recipient with a clusterin level that is significantly higher than the clusterin level in the control as being at an increased risk of developing interstitial fibrosis or tubular atrophy.
    Type: Application
    Filed: April 17, 2013
    Publication date: May 14, 2015
    Inventors: Barbara Murphy, Philip J. O'Connell
  • Publication number: 20150126444
    Abstract: CTP-modified human growth hormone polypeptides and pharmaceutical formulations and pharmaceutical compositions comprising the same and methods of producing, and using the same are disclosed.
    Type: Application
    Filed: December 10, 2014
    Publication date: May 7, 2015
    Inventors: FUAD FARES, UDI EYAL FIMA
  • Publication number: 20150126445
    Abstract: A polypeptide and polynucleotides comprising at least two carboxy-terminal peptides (CTP) of chorionic gonadotrophin attached to a non-human peptide-of-interest are disclosed. Pharmaceutical compositions comprising the non-human polypeptides and polynucleotides of the invention and methods of using both human and non-human polypeptides and polynucleotides are also disclosed.
    Type: Application
    Filed: December 10, 2014
    Publication date: May 7, 2015
    Inventors: FUAD FARES, UDI EYAL FIMA
  • Publication number: 20150119325
    Abstract: The present invention provides methods for the high-level production of recombinant human erythropoietin (rhuEPO) derivative, asialoerythropoietin (asialo-rhuEPO), in plants. The methods for producing asialo-rhuEPO comprise making a plant or at least one plant cell that comprises a promoter that drives expression in a plant cell operably linked to a polynucleotide encoding a human erythropoieting fusion protein and a promoter that drives expression in a plant cell operably linked to a polynucleotide encoding N-glycosylation modification enzyme, particularly a mammalian ?1,4-galactosyltransferase. The present invention further provides plants, plant cells, and seeds that have been genetically modified to produce high levels of asialo-rhuEPO. Additionally, provided are methods for purifying asialo-rhuEPO from plant tissues.
    Type: Application
    Filed: March 14, 2013
    Publication date: April 30, 2015
    Applicant: NORTH CAROLINA CENTRAL UNIVERSITY
    Inventors: Jiahua Xie, Farooqahmed S. Kittur, Chiu-Yueh Hung
  • Publication number: 20150093356
    Abstract: Invented are non-peptide TPO mimetics. Also invented are novel processes and intermediates used in the preparation of the presently invented compounds. Also invented is a method of treating thrombocytopenia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a selected hydroxy-1-azobenzene derivative.
    Type: Application
    Filed: December 11, 2014
    Publication date: April 2, 2015
    Inventor: Connie ERICKSON-MILLER
  • Patent number: 8987190
    Abstract: The present invention relates a method for the treatment of intracranial bleeding comprising administration of a therapeutically effective amount of tPa and a therapeutically effective amount of carbamylated erythropoietin.
    Type: Grant
    Filed: November 15, 2010
    Date of Patent: March 24, 2015
    Assignee: H. Lundbeck A/S
    Inventors: Thomas Nikolaj Sager, Michael Chopp, Zheng Gang Zhang
  • Publication number: 20150065425
    Abstract: Osteogenic compositions include a decellularized extracellular matrix tissue and bone morphogenic protein, preferably BMP-2. The compositions make beneficial use of the BMP, which can be used at relatively low doses and can bind to native components (e.g., native sulfated glycosaminoglycans such as heparin and/or heparan sulfate) remaining in the decellularized extracellular matrix tissue. Methods for preparation and use of such compositions are also described. The compositions and related methods can be used in the treatment of diseased or damaged bone tissue.
    Type: Application
    Filed: September 2, 2014
    Publication date: March 5, 2015
    Inventors: Shelley L. Wallace, Amanda F. Taylor, Steven Charlebois, Christine M. Steinhart, Neal E. Fearnot
  • Patent number: 8968716
    Abstract: Disclosed herein are an in situ-forming, bioadhesive hydrogel and the medical uses thereof. Being formed by in situ crosslinking through an enzymatic reaction, the hydrogel has an advantage over conventional bioadhesive hydrogels in terms of biocompatibility. In addition, the in situ-forming bioadhesive hydrogel has excellent biocompatibility and mechanical strength and has excellent tissue adhesiveness thanks to modification with/without dopa derivatives. The hydrogel finds a variety of applications in the biomedical field, including bioadhesives or hemostats, implant substances for tissue regeneration and augmentation, carriers for delivering biologically active materials or drugs, etc.
    Type: Grant
    Filed: September 2, 2010
    Date of Patent: March 3, 2015
    Assignee: Ajou University Industry-Academic Cooperation Foundation
    Inventors: Ki-Dong Park, Yoon-Ki Joung, Kyung-Min Park, Eu-Gene Lih
  • Patent number: 8952061
    Abstract: The present invention discloses the signaling pathway involved erythroid repression by iron deficiency. Further disclosed is anon-toxic small-molecule compound which potently reverses the erythroid repression caused by iron deficiency. The present invention further encompasses novel compounds for inhibition of red cell production, useful, for example, in the treatment of polycythemia vera, a malignancy causing uncontrolled red cell production. These inhibitory compounds also promote megakaryocytic lineage commitment and may therefore be useful for augmentation of platelet production. The present invention further discloses isocitrate reversal of iron deprivation.
    Type: Grant
    Filed: November 19, 2012
    Date of Patent: February 10, 2015
    Assignee: University of Virginia Patent Foundation
    Inventors: Adam N. Goldfarb, Loretta L. Delehanty
  • Publication number: 20150018274
    Abstract: The present invention provides isolated stabilized EPO-derived peptides and their mimics that protect against tissue damage in subjects having diverse forms of neural and non-neural organ system injury, pharmaceutical compositions containing the isolated stabilized EPO-derived peptides, methods for treating symptoms of a disease, disorder or condition having an inflammatory or an autoimmune component in a subject in need thereof, and methods for downregulating immune mediator activity in a subject in need thereof.
    Type: Application
    Filed: January 23, 2014
    Publication date: January 15, 2015
    Applicant: UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY
    Inventors: Yasuhiro Maeda, Rui Rong Yuan, Joseph Menonna, Wei Ping Li, Peter Dowling
  • Patent number: 8933026
    Abstract: The present invention relates to a compound which is a polysaccharide derivative of EPO, or of an EPO like protein, wherein the polysaccharide is anionic and comprises between 2 and 200 saccharide units. The present invention also relates to pharmaceutical compositions comprising the novel compounds, and methods for making the novel compounds.
    Type: Grant
    Filed: June 24, 2014
    Date of Patent: January 13, 2015
    Assignee: Lipoxen Technologies Limited
    Inventors: Sanjay Jain, Peter Laing, Gregory Gregoriadis, Norbert Oskar Rumpf
  • Publication number: 20140378378
    Abstract: Provided are a peptide, which has an amino acid sequence of SEQ ID NO. 1 and is effective for the prevention of cell damage, and a pharmaceutical composition for preventing cell damage, the pharmaceutical composition including the peptide as an active component. The peptide according to the present invention not only exhibits substantially better biological activities than conventional natural human erythropoietin in terms of various cell protection activities, but also has a substantially simpler structure than the natural human erythropoietin. Thus, the peptide may easily pass through a tissue-blood barrier and is economically advantageous due to its low production cost.
    Type: Application
    Filed: September 29, 2012
    Publication date: December 25, 2014
    Inventor: Hoojung Kim
  • Patent number: 8916616
    Abstract: Multifunctional polymers are disclosed having a smart segment and a biodegradable segment. Advantageously, the biodegradable segment includes a hydrophilic segment and a hydrophobic segment. Embodiments include combining the multifunctional polymeric material with a biologically active substance in an aqueous loading environment and administering the composition as a drug delivery vehicle to a human subject.
    Type: Grant
    Filed: August 27, 2013
    Date of Patent: December 23, 2014
    Assignee: University of Tennessee Research Foundation
    Inventors: Tao Lu Lowe, Young Shin Kim, Xiao Huang
  • Publication number: 20140356323
    Abstract: The present invention provides compositions comprising isolated human collagen, isolated human elastin and a pharmaceutically acceptable carrier wherein the human elastin is substantially insoluble in water with a molecular weight greater than 100 kDa. The present invention further provides methods and kits for soft tissue augmentation.
    Type: Application
    Filed: August 18, 2014
    Publication date: December 4, 2014
    Inventors: Laura E. Niklason, Yuling Li, Juliana Blum, Shannon L.M. Dahl, Geoffrey Erickson, Frank Zeigler
  • Publication number: 20140349927
    Abstract: Methods for treating individuals suffering from inflammation, specifically systemic inflammation including septic shock and inflammatory conditions affecting the gastrointestinal, myocardial and endocrine systems with ladostigil.
    Type: Application
    Filed: August 6, 2014
    Publication date: November 27, 2014
    Inventor: Marta Weinstock-Rosin
  • Publication number: 20140341889
    Abstract: The present invention is based, at least in part, on the identification of a pharmaceutical container formed, at least in part, of a glass composition which exhibits a reduced propensity to delaminate, i.e., a reduced propensity to shed glass particulates. As a result, the presently claimed containers are particularly suited for storage of pharmaceutical compositions and, specifically, a pharmaceutical solution comprising a pharmaceutically active ingredient, for example, Prolia® (denosumab), Xgeva® (denosumab), Aranesp® (darbepoetin alfa), AMG-145, romosozumab (AMG-785), ganitumab (AMG-479), trebananib (AMG-386), brodalumab (AMG-827), and rilotumumab (AMG-102).
    Type: Application
    Filed: April 23, 2014
    Publication date: November 20, 2014
    Applicant: CORNING INCORPORATED
    Inventors: Wendell P. Weeks, Robert Anthony Schaut, Steven Edward DeMartino, John Stephen Peanasky
  • Publication number: 20140323401
    Abstract: The present invention is directed to novel tissue protective peptides. The tissue protective peptides of the invention may bind to a tissue protective receptor complex. In particular, the present invention is drawn to tissue protective peptides derived from or sharing consensus sequences with portions of cytokine receptor ligands, including Erythropoietin (EPO), that are not involved in the binding of the ligand to the receptor complex, e.g., to the EPO receptor homodimer. Accordingly, the tissue protective peptides of the invention are derived from the amino acid sequences of regions of cytokine receptor ligands that are generally located on or within the region of the ligand protein that is opposite of the receptor complex, i.e., are generally derived from amino acid sequences of regions of the ligand protein that face away from the receptor complex while the ligand is bound to the receptor.
    Type: Application
    Filed: April 8, 2014
    Publication date: October 30, 2014
    Applicant: Araim Pharmaceuticals, Inc.
    Inventors: Anthony CERAMI, Michael BRINES, Thomas COLEMAN
  • Publication number: 20140315802
    Abstract: The present invention relates to a compound which is a polysaccharide derivative of EPO, or of an EPO like protein, wherein the polysaccharide is anionic and comprises between 2 and 200 saccharide units. The present invention also relates to pharmaceutical compositions comprising the novel compounds, and methods for making the novel compounds.
    Type: Application
    Filed: June 24, 2014
    Publication date: October 23, 2014
    Applicant: LIPOXEN TECHNOLOGIES LIMITED
    Inventors: Sanjay Jain, Peter Laing, Gregory Gregoriadis, Norbert Oskar Rumpf
  • Publication number: 20140314759
    Abstract: In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.
    Type: Application
    Filed: March 7, 2014
    Publication date: October 23, 2014
    Applicant: ACCELERON PHARMA, INC.
    Inventors: Jasbir Seehra, Robert Scott Pearsall, Ravindra Kumar
  • Publication number: 20140309166
    Abstract: The present invention relates to a compound which is a polysaccharide derivative of EPO, or of an EPO like protein, wherein the polysaccharide is anionic and comprises between 2 and 200 saccharide units. The present invention also relates to pharmaceutical compositions comprising the novel compounds, and methods for making the novel compounds.
    Type: Application
    Filed: June 24, 2014
    Publication date: October 16, 2014
    Applicant: LIPOXEN TECHNOLOGIES LIMITED
    Inventors: Sanjay Jain, Peter Laing, Gregory Gregoriadis, Norbert Oskar Rumpf
  • Publication number: 20140302144
    Abstract: The invention relates to a pharmaceutical formulation for sustained delivery of a therapeutic agent, preferably a protein, polypeptide, an antibody or an antibody fragment, comprising one or more gel forming peptides wherein the formulation exhibits sustained delivery for at least two weeks, three weeks, four weeks, five weeks, six weeks, seven weeks, eight weeks, nine weeks, ten weeks, eleven weeks, twelve weeks or more. In one embodiment, the invention relates to a formulation comprising self-assembling peptides that undergo sol-gel transition in the presence of an electrolyte solution such as biological fluids and salts. The formulation can provide sustained release of antibody and antibody fragments, in particular, IgG. Antibody diffusivities can be decreased with increasing hydrogel nanofiber density, providing a means to control the release kinetics.
    Type: Application
    Filed: March 14, 2014
    Publication date: October 9, 2014
    Applicant: Massachusetts Institute of Technology
    Inventors: Sotirios Koutsopoulos, Shuguang Zhang
  • Publication number: 20140301975
    Abstract: Methods of treating blood disorders are described.
    Type: Application
    Filed: June 20, 2014
    Publication date: October 9, 2014
    Inventor: Susan P. Perrine
  • Publication number: 20140294762
    Abstract: The invention includes methods and compositions for remodeling a peptide molecule, including the addition or deletion of one or more glycosyl groups to a peptide, and/or the addition of a modifying group to a peptide.
    Type: Application
    Filed: April 7, 2014
    Publication date: October 2, 2014
    Applicant: Novo Nordisk A/S
    Inventors: Shawn DeFrees, David A. Zopf, Robert J. Bayer, David James Hakes, Caryn L. Bowe, Xi Chen
  • Patent number: 8840879
    Abstract: Conjugates of hydroxyalkyl starch and a protein are provided herein. The conjugates are formed by a covalent linkage between the hydroxyalkyl starch or a derivative of the hydroxyalkyl starch and the protein. Methods of producing the conjugates and the use of the conjugates also are provided herein.
    Type: Grant
    Filed: February 1, 2011
    Date of Patent: September 23, 2014
    Assignee: Fresenius Kabi Deutschland GmbH
    Inventors: Wolfram Eichner, Martin Schimmel, Frank Hacket, Elmar Kraus, Norbert Zander, Ronald Frank, Harald Conradt, Klaus Langer, Michele Orlando, Klaus Sommermeyer
  • Publication number: 20140271507
    Abstract: The present invention provides a skin care composition for maintaining or improving the healthy appearance of the skin of an individual and/or rejuvenate the skin of an individual. A skin care composition comprises active ingredients, including, without limitation, growth factors, anti-oxidants, curcuminoids, oils and/or red rice extracts. Among the growth factors comprising biologically active ingredients of the skin care composition are insulin like growth factor (IGF), an epidermal growth factor protein (EGFP), an insulin-like growth factor (IGF), a transforming growth factor beta (TGF?), and erythropoiesis stimulating agent (ESA). The invention further provides a skin care composition for topical use to maintain or improve the health of the skin of an individual and/or rejuvenate the skin of an individual.
    Type: Application
    Filed: March 13, 2014
    Publication date: September 18, 2014
    Applicant: Stemetrix, Inc.
    Inventors: Dwain Morris-Irvin, Bradley Brownstein
  • Publication number: 20140256629
    Abstract: The described invention provides methods and kits for administering an EPO-derived peptide to a subject suffering from a neurodegenerative disease. The EPO-derived peptide delays the onset and/or progression of a neurodegenerative disease, limits cognitive impairment in, and prolongs the survival of, subjects suffering from a neurodegenerative disease.
    Type: Application
    Filed: March 11, 2013
    Publication date: September 11, 2014
    Inventors: Wei Lu, Rui Rong, Peter C. Dowling
  • Publication number: 20140234402
    Abstract: Compositions and methods for treating systemic diseases by intravenous administration of formulations of synthesized curcumin (diferuloylmethane) and concomitantly a calcium channel blocker to human subjects with neoplastic and neurodegenerative diseases are disclosed herein. The diseases are treated by prolonged administration of sub-optimal doses of liposomal curcumin or polymeric nanocurcumin or the sustained release curcumin from PLGA nanocurcumin at dosages below systemic hemolytic thresholds concomitantly with or without calcium channel blockers.
    Type: Application
    Filed: April 30, 2014
    Publication date: August 21, 2014
    Applicant: SignPath Pharma Inc.
    Inventor: Lawrence Helson
  • Publication number: 20140227222
    Abstract: The presently disclosed subject matter relates to methods and compositions for protecting healthy cells from damage due to DNA damaging agents. In particular, the presently disclosed subject matter relates to the protective action of selective cyclin dependent kinase 4/6 (CDK4/6) inhibitors administered to subjects that have been exposed to or that are at risk of exposure to DNA damage.
    Type: Application
    Filed: December 11, 2013
    Publication date: August 14, 2014
    Applicant: The University of North Carolina at Chapel Hill
    Inventors: Norman E. Sharpless, Patrick J. Roberts, Kwok Wong, Yan Liu, Soren Johnson
  • Publication number: 20140219995
    Abstract: Organic compounds showing the ability to inhibit effector toxin secretion or translocation mediated by bacterial type III secretion systems are disclosed. The disclosed type III secretion system inhibitor compounds are useful for combating infections by Gram-negative bacteria such as Salmonella spp., Shigella flexneri, Pseudomonas spp., Yersinia spp., enteropathogenic and enteroinvasive Escherichia coli, and Chlamydia spp. having such type III secretion systems.
    Type: Application
    Filed: July 13, 2012
    Publication date: August 7, 2014
    Applicant: MICROBIOTIX, INC.
    Inventors: Donald T. Moir, Daniel Aiello, Norton P. Peet, John D. Williams, Matthew Torhan
  • Patent number: 8796207
    Abstract: The present invention relates to a compound which is a polysaccharide derivative of EPO, or of an EPO like protein, wherein the polysaccharide is anionic and comprises between 2 and 200 saccharide units. The present invention also relates to pharmaceutical compositions comprising the novel compounds, and methods for making the novel compounds.
    Type: Grant
    Filed: October 5, 2012
    Date of Patent: August 5, 2014
    Assignee: Lipoxen Technologies Limited
    Inventors: Gregory Gregoriadis, Sanjay Jain, Peter Laing, Norbert Oskar Rumpf
  • Patent number: 8796206
    Abstract: The present invention relates to stable aqueous protein formulations. In particular, disclosed herein are therapeutic protein formulations suitable for parenteral administration having one or more antioxidants.
    Type: Grant
    Filed: November 13, 2008
    Date of Patent: August 5, 2014
    Assignee: Amgen Inc.
    Inventors: Christopher James Sloey, Jason Ko, Tiansheng Li
  • Publication number: 20140200181
    Abstract: A method of adjusting a patient's undesired hematocrit and/or hemoglobin concentration to a value within a desired range at a predetermined time with an erythropoiesis stimulating agent (ESA) regimen includes obtaining patient parameters required for input into a model for predicting the patient's hematocrit and/or hemoglobin concentration at a predetermined time with a selected ESA administration regimen, and employing the patient parameters and an initially selected EPO administration regimen in the model to predict the patient's hematocrit and/or hemoglobin concentration at the predetermined time with the initially selected ESA administration regimen.
    Type: Application
    Filed: September 7, 2012
    Publication date: July 17, 2014
    Inventors: Doris Helene Fuertinger, Franz Kappel, Peter Kotanko, Nathan W. Levin, Stephan Thijssen
  • Publication number: 20140200180
    Abstract: Methods for producing proteins and glycoproteins in Pichia pastoris that lack detectable cross binding activity to antibodies made against host cell antigens are described. In particular, methods are described wherein recombinant Pichia pastoris strains that do not display a ?-mannosyltransferase 2 activity with respect to an N-glycan or O-glycan and do not display at least one activity selected from a ?-mannosyltransferase 1, 3, and 4 activity to produce recombinant proteins and glycoproteins. These recombinant Pichia pastoris strains can produce proteins and glycoproteins that lack detectable ?-mannosidase resistant ?-mannose residues thereon and thus, lack cross binding activity to antibodies against host cell antigens. Further described are methods for producing bi-sialylated human erythropoietin in Pichia pastoris that lack detectable cross binding activity to antibodies against host cell antigens.
    Type: Application
    Filed: January 15, 2014
    Publication date: July 17, 2014
    Applicant: Merck Sharp & Dohme Corp
    Inventors: Piotri Bobrowicz, Sujatha Gomathinayagam, Stephen Hamilton, Huijuan Li, Natarajan Setheraman, Terrance A. Stadheim, Stephan Wildt
  • Publication number: 20140193360
    Abstract: The present invention relates to an adhesive hydrogel composition containing catechol group-coupled chitosan and Pluronic comprising a thiol group coupled to the end thereof, and more specifically, to an adhesive composition which is safe in vivo and in vitro, is temperature sensitive, and has an excellent hemostatic effect and thus can be used as a bioadhesive, and a medical adhesive, an adhesion barrier and a surface adsorption inhibitor comprising the same.
    Type: Application
    Filed: November 21, 2011
    Publication date: July 10, 2014
    Applicant: Innotherapy Inc.
    Inventors: Haeshin Lee, Moon Sue Lee, Ji Hyun Ryu
  • Publication number: 20140193393
    Abstract: Methods of using an ETB receptor agonist, such as IRL-1620, for the treatment of stroke or cerebrovascular accidents are disclosed. The ETB receptor agonist is used alone or in combination with a second agent useful in the treatment of stroke or other cerebrovascular accident.
    Type: Application
    Filed: January 7, 2014
    Publication date: July 10, 2014
    Applicant: MIDWESTERN UNIVERSITY
    Inventor: ANIL GULATI
  • Patent number: 8765924
    Abstract: This invention relates to novel protein conjugates, in particular, to novel pegylated proteins, and their methods of making and use. One aspect of the present invention relates to pegylated-erythropoietin having greater clinical efficacy and stability during shipment and storage than current erythropoietin formulations.
    Type: Grant
    Filed: July 16, 2007
    Date of Patent: July 1, 2014
    Assignee: Prolong Pharmaceuticals, Inc.
    Inventors: Abraham Abuchowski, Lihsyng Stanford Lee